[Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018013475
German
Original Title: Idecabtagen vicleucel (multiples Myelom, ≥ 2 Vortherapien)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a24-81.html
Year Published: 2024
URL for published report: https://www.iqwig.de/download/a24-81_idecabtagen-vicleucel_addendum-zum-projekt-a24-35_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A24-81
MeSH Terms
  • Receptors, Chimeric Antigen
  • Multiple Myeloma
  • Antineoplastic Agents, Immunological
  • Immunotherapy, Adoptive
Keywords
  • Idecabtagene Vicleucel
  • Multiple Myeloma
  • Benefit Assessment
  • NCT03651128
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.